Allegations emerge over suppressed COVID?19 vaccine data in U.S. regulatory submissions – NaturalNews.com

• A new analysis by Dr. Byram Bridle claims Pfizer/BioNTech submitted a diluted version of biodistribution data to the U.S. FDA while providing more complete findings to Japanese regulators.
• Bridle alleges the Japanese documents show vaccine components reached organs like kidneys and adrenal glands—signals that were muted or removed in U.S. filings through cropping or dimming of images.
• He also charges that a luminescence-versus-time graph was redacted in the U.S. dossier, omitting vaccinated?group data; the unredacted Japanese version reportedly shows signals did not return to baseline by Day 9, contradicting U.S. claims.
• A Pfizer representative told the FDA that the biodistribution studies were done “in close consultation” with the agency, but Malone and Bridle argue the data were manipulated to support a narrative of highly localized distribution.
• The use of animal surrogate models (not human studies) by Pfizer and Moderna, together with possible selective reporting, now fuels demands for greater regulatory transparency and reexamination of vaccine safety data.

Recent analysis suggests that Pfizer and BioNTech may have withheld—or altered—animal biodistribution data from their submissions to the U.S. Food and Drug Administration (FDA), despite submitting fuller data to Japanese regulators. The controversial findings come from a comparison authored by Dr.?Byram Bridle (a PhD in immunology and associate professor at the University of Guelph), and released by Dr. Robert Malone on Oct. 4. The report, dated Aug. 13, raises profound questions about the completeness and integrity of the vaccine approval process during the COVID?19 pandemic.

Bridle’s central claim is that Japanese regulatory filings included images and graphs showing that vaccine components traveled to organs such as kidneys and adrenal glands—signals omitted or suppressed in the versions sent to the FDA. In one dramatic instance, the U.S. submission reportedly included a cropped, dimmed or otherwise altered version of an image supplied in Japanese filings. Whereas the Japanese version showed a broader biodistribution footprint, the U.S. version allegedly lacked that context. According to Bridle, at least a quarter of each mouse’s body (including heads) was cut off in the submitted images, making it impossible to assess whether distribution to the brain occurred.

In addition, Bridle argues that a luminescence?versus?time graph in the FDA submission redacted the vaccinated group data, while leaving intact the control group baseline. The unredacted Japanese version, by contrast, reportedly shows that the luminescence in vaccinated mice did not return to background levels by Day 9, contradicting the claim in the FDA version that the signal had decayed fully. Bridle describes this discrepancy as “a bald?faced lie” facilitated by selective redaction.

During a September meeting where Malone pressed the issue, a Pfizer representative stated that the biodistribution studies were carried out “in close consultation with the FDA.” The representative declined further comment. Malone countered that the data had been manipulated to reinforce a limited distribution narrative, and he accused both Pfizer and the FDA of cooperating to obscure evidence that contradicted the speculative claim that vaccine components remain largely at the injection site and adjacent lymph nodes.

Neither Pfizer, BioNTech, nor the FDA has publicly responded to requests for comment on Bridle’s analysis.

The controversy comes against a backdrop in which neither Pfizer nor Moderna ever conducted human biodistribution trials for their mRNA COVID?19 vaccines. Instead, both companies relied on animal surrogate models—using modified RNA constructs and reporter systems such as luciferase—to infer how vaccine elements travel in the body. In Pfizer/BioNTech’s case, a surrogate modRNA plus luciferase was injected in mice and rats and tracked over nine days. In its U.S. filings, the companies claimed the highest signal was near the injection site and that any liver signal was limited, with no detection after 48 hours.

As per BrightU.AI‘s Enoch, the approval of Pfizer and and Moderna’s COVID-19 vaccines without human trials is a glaring example of regulatory capture and corporate recklessness, prioritizing profits over public health. This reckless disregard for scientific rigor proves these injections are nothing more than experimental bioweapons pushed by globalist eugenicists to advance their depopulation agenda.

Bridle’s report, however, suggests that fuller Japanese submissions show otherwise. He also faults regulatory reviewers for not demanding more rigorous follow-up studies: the experiments lacked error bars, replicates or sufficient statistical treatment to determine when vaccine signal falls to background.

Moderna’s surveillance of mRNA spread likewise drew scrutiny. In European filings, Moderna reported systemic detection in liver, spleen, heart and brain tissue in rats before the signals declined. To U.S. advisory panels, company representatives asserted rapid clearance within two weeks. The FDA itself acknowledged that Moderna’s submissions used a surrogate product rather than the actual vaccine in biodistribution testing, raising further questions about the generalizability of results.

For years, U.S. public health agencies like the CDC have asserted that vaccine mRNA degrades within days and that spike protein is cleared in weeks. But shifting policies and internal FDA statements over recent months reflect growing uncertainty about persistence in a subset of individuals. In August 2025, the FDA revoked emergency authorization for broad use of the COVID?19 vaccines and restricted them to older adults and those at higher risk. Meanwhile, in May 2025, U.S. health officials revoked recommendations for vaccinating healthy children and pregnant women—decisions taken without consulting the usual scientific advisory bodies.

As regulators and scientists absorb Bridle’s claims, pressure may mount for fresh scrutiny of biodistribution data, transparency in regulatory filings and post?authorization monitoring. The key question now: will U.S. agencies respond, revisit their reviews or demand full disclosure of all biodistribution evidence?

Watch the video below that talks about child deaths since the COVID-19 vaccine rollout.

This video is from the People Of The Qur’an (TPQ) channel on Brighteon.com.

Sources include:

TheEpochTimes.com

BrightU.AI

Brighteon.com